Inhibition of corneal neovascularization with a nutrient mixture containing lysine, proline, ascorbic acid, and green tea extract.
Corneal neovascularization is a significant, sight-threatening complication of many ocular surface disorders. Various growth factors and proteinases are involved in corneal neovascularization. The data supporting a causal role for vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) are extensive. Inhibition of VEGF and MMPs is a main strategy for treating corneal neovascularization. Several findings have shown that corneal neovascularization can be reduced by using anti-VEGF and anti-MMPs agents. Efficacy of a nutrient mixture (NM) containing lysine, proline, ascorbic acid, and green tea extract has been demonstrated for reducing VEGF and MMPs secretion by various cells. Moreover, NM can inhibit endothelial cell migration and capillary tube formation. We herein note that topical application of NM is potentially useful for inhibiting corneal neovascularization and restoration of corneal clarity. Further investigations in animal models are needed to place NM alongside corneal neovascularization therapeutics.
Shakiba
Yadollah
Y
Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran. y_shakiba@yahoo.com
Mostafaie
Ali
A
D000287:Administration, Topical; D000818:Animals; D001205:Ascorbic Acid / Q000008:administration & dosage* / Q000494:pharmacology*; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D003864:Depression, Chemical; D004338:Drug Combinations; D006801:Humans; D008239:Lysine / Q000008:administration & dosage* / Q000494:pharmacology*; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism / Q000502:physiology; D009883:Ophthalmic Solutions; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage* / Q000494:pharmacology*; D011392:Proline / Q000008:administration & dosage* / Q000494:pharmacology*; D013662:Tea / Q000737:chemistry*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000502:physiology
D004338:Drug Combinations; D061965:Matrix Metalloproteinase Inhibitors; D009883:Ophthalmic Solutions; D010936:Plant Extracts; D013662:Tea; D042461:Vascular Endothelial Growth Factor A; D011392:Proline; D020782:Matrix Metalloproteinases; D008239:Lysine; D001205:Ascorbic Acid